Recall Therapeutics
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Recall Therapeutics is pioneering a breakthrough platform for memory restoration by discovering a new mechanism of action in Alzheimer’s disease, neurodegenerative diseases, oncology-related cachexia, and aging-associated sarcopenia, addressing multi-billion-dollar markets with a unified, disease-modifying approach.
Company HQ City:
Naples
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2024
Lead Product in Development:
RTX-100 for Alzheimer's and RTX-200 for Oncology Cachexia
CEO
Dan Salain President & CEO
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
August 2026
What is your next catalyst (value inflection) update?
NHP data June/July 2026
PreIND FDA meeting August 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}